Applicability of HLA-B*5801 Allele Detection in Allopurinol Irritated Severe Allergic Reactions

doi:10.19803/j.1672-8629.2021.08.16

Abstract

Abstract: Objective To analyze the detection results of HLA-B*5801 and clinical applicability of allopurinol in our hospital in order to provide information for preventing allopurinol-caused adverse reactions. Methods The clinical information about patients who had their HLA-B*5801 detected between January 1, and December 31, 2017 in our hospital was retrospectively analyzed. The applicability of gene detection results was assessed. Results A total of 55 patients who had received gene detection were collected, including 39 from the Department of Nephrology, 13 from the Department of Dermatology, and 3 from the Department of Endocrinology. There were 17 (30.91%) HLA-B*5801 allele positive cases,38 (69.09%) negative cases. Thirteen patients suffered from cutaneous adverse reactions after allopurinol treatment, eleven of whom were HLA-B*5801 allele positive and 2 were negative. Among these patients, 30 (54.55%) had had their HLA-B*5801 gene tested before allopurinol therapy according to the guidelines. Conclusion The proportion of patients who have their HLA-B*5801 gene detected before allopurinol therapy in our hospital is relatively low. The pharmaceutical department should strengthen the supervision of clinical use of allopurinol. It is recommended that this drug be used according to the results of gene test to minimize the risk of adverse reactions.

Key words: HLA-B*5801, allopurinol, adverse drug reactions

CLC Number:

R994.11

FANG Ling, DONG Ming, WANG Yanyan. Applicability of HLA-B*5801 Allele Detection in Allopurinol Irritated Severe Allergic Reactions[J]. Chinese Journal of Pharmacovigilance, 2021, 18(8): 772-775.

References

[1] Liu R, Han C, Wu D, et al.Prevalence of hyperuricemia and gout in mainland China from 2000 to 2014: a systematic review and meta-analysis[J]. Biomed Res Int, 2015, 2015(10): 762-820.
[2] Cheng L, Xiong Y, Qin CZ, et al.HLA-B*58:01 is strongly associated with allopurinol-induced severe cutaneous adverse reactions in Han Chinese patients: a multicentre retrospective case-control clinical study[J]. Br J Dermatol, 2015, 173(2): 555-558.
[3] Wu R, Cheng YJ, Zhu LL, et al.Impact of HLA-B*5801 allele and allopurinol-induced cutaneous adverse drug reactions: evidence from 21 pharmacogenetic studies[J]. Oncotarget, 2016, 7(49): 81870-81879.
[4] Zhang X, Ma H, Hu C, et al.Detection of HLA-B*58:01 with TaqMan assay and its association with allopurinol-induced sCADR[J]. Clin Chem Lab Med, 2015, 53(3): 383-390.
[5] Khanna D, Fitagerald JD, Khanna PP, et al.2012 american college of rheumatology guidelines for management of gout. part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia[J]. Arthritis Care Res (Hoboken), 2012, 64(10): 1431-1446.
[6] Chinese society of endocrinology. Guideline for the diagnosis and management of hyperuricemia and gout in China (2019)[J]. Chin J Endocrinol Metab(中华内分泌代谢杂志), 2020, 36(1): 1-13.
[7] Hung SI, Chung WH, Liou LB, et al.HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol[J]. Proc Natl Acad Sci USA, 2005, 102(11): 4134-4139.
[8] Jutkowitz E, Dubreuil M, Lu N, et al.The cost-effectiveness of HLA-B*5801 screening to guide initial urate-lowering therapy for gout in the United States[J]. Semin Arthritis Rheum, 2017, 46(5): 594-600.
[9] Deng ZY, Yang J, Yang WL.Detection of the HLA-B* 5801 allele in Han Chinese with allopurinol-induced severe drug eruption[J]. Diagn Ther J Dermatol-Venereol(皮肤性病诊疗学杂志), 2013, 20(6): 379-382.
[10] Ng CY, Yeh YT, Wang CW, et al.Impact of the HLA-B(*)5801 allele and renal impairment on allopurinol-induced cutaneous adverse reactions[J]. J Invest Dermatol, 2016, 136(7): 1373-1381.
[11] Wang CW, Dao RL, Chung WH.Immunopathogenesis and risk factors for allopurinol severe cutaneous adverse reactions[J]. Curr Opin Allergy Clin Immunol, 2016, 16(4): 339-345.
[12] Wang CT.Risk analysis and measures of toxic epidermal necrosis caused by allopurinol[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2014, 11(8): 485-487.

[1]	CAO Guiping, DENG Linlin, ZHU Ganhong, LU Ying, MA Shuang, CHEN Linlin, Liu Lili. One case of severe liver injury caused by Tianma Shouwu tablets [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 216-218.
[2]	GUO Longxin, GAO Yunjuan, WU Chengzhao, LONG Minjuan, ZHU Shengkai, SONG Haibo, ZHAO Xu, XIAO Xiaohe. Exploring new risk signals and susceptibility factors of traditional Chinese medicine-induced hepatotoxicity based on big data from adverse reaction monitoring [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 15-19.
[3]	JIANG Wenshuo, YANG Li. Adverse drug reaction among 694 patients in an epilepsy physician-pharmacist joint clinic [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 102-106.
[4]	CHEN Huayan, JIANG Dongbo, GUO Chunlian, YANG Jiaqi, LI Yuxin, CAI Weiming. Safety of nirmatrelvir/ritonavir in the treatment of novel coronavirus infections [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 107-110.
[5]	LI Xiaozhu, WANG Qiang, PANG Yu, ZHANG Yijing. Management of individual adverse drug reaction reports [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 975-977.
[6]	LIU Wendong, CUI Huanhuan, WANG Xiaohan, SU Xian, WANG Haixue. Status and thinking of Parmacovigilance regulatory system during clinical trials of the pediatric drug in China [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1002-1006.
[7]	ZANG Tianying, LIU Bingyang, TANG Xiaojun. Differentiation of vancomycin induced anaphylactoid and anaphylactic reactions [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1078-1080.
[8]	CHANG Yongzhuo, LI Ji, ZHANG Xiaoyan, ZHOU Chaofan. One case of abnormal uterine bleeding caused by Baofukang suppository [J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 935-938.
[9]	WANG Shuwei, YIN Jinjun, WANG Bing, SONG Caiping, YANG Fujun. Axitinib tablets combined with toripalimab injection in the treatment of renal cancer-induced central retinal artery occlusion: a case report [J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 825-828.
[10]	ZHENG Yi, LUO Xiao, ZHANG Pengpeng, LIU Yongmei, YE Xiaofei, GUO Xiaojing, CHEN Xia, HE Jia. Adverse reactions of immune checkpoint inhibitor myocarditis based on active monitoring system [J]. Chinese Journal of Pharmacovigilance, 2023, 20(6): 634-638.
[11]	LI Tan, ZHANG Yang, ZHANG Wangde, WANG Yun. Efficacy and safety of different analgesia drugs in the treatment of lower extremity ischemic pain [J]. Chinese Journal of Pharmacovigilance, 2023, 20(6): 680-683.
[12]	CHEN Chongze, LI Jie, KUANG Lian, TAN Xuewen, LIU Minhui, LIU Xi, ZHENG Yanchai, JIN Hongtao. Characterization of adverse reactions associated with drug-induced liver injury in 448 inpatients [J]. Chinese Journal of Pharmacovigilance, 2023, 20(6): 697-704.
[13]	. Annual report of national adverse drug reaction monitoring (2022) [J]. Chinese Journal of Pharmacovigilance, 2023, 20(6): 712-719.
[14]	CHEN Cheng, DENG Li, LIU Songqing, DU Qian, XI Xin. Analysis of reports of allergic shock in Chongqing between 2015 and 2020 [J]. Chinese Journal of Pharmacovigilance, 2023, 20(4): 460-464.
[15]	OUYANG Ying, ZHONG Changxin, XIA Chunhua, NIE Jungang, ZHOU Ying. One case of breast hyperplasia caused by digoxin tablets [J]. Chinese Journal of Pharmacovigilance, 2023, 20(3): 346-347.